Synthesis and multilevel evaluation of benzimidazole-based anticancer compounds: DNA/serum albumin interaction, and in-depth theoretical insights
Sevgi Kundu, Senem Akkoc, Yalçın Erzurumlu, Sadeq K Alhag, Lamya Ahmed Alkeridis, Mehran Feizi-Dehnayebi · 2026
Read Synthesis and multilevel evaluation of benzimidazole-based anticancer compounds: DNA/serum albumin interaction, and in-depth theoretical insights by Sevgi Kundu, Senem Akkoc, Yalçın Erzurumlu, Sadeq K Alhag, Lamya Ahmed Alkeridis, Mehran Feizi-Dehnayebi (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13524987.txt.
Description
Sevgi Kundu and colleagues synthesize and evaluate, in a 2026 multilevel study, two new benzimidazole-based compounds as candidate anticancer agents. Benzimidazoles are a versatile drug scaffold. The pair, labeled 3a and 3b, were made in two steps and tested against healthy kidney cells plus lung, breast, and liver cancer lines.
Compound 3b showed strong killing of liver and breast cancer cells at concentrations near eleven micromolar. Treated breast cancer cells raised pro-death genes and lowered survival genes, showed higher oxidative stress, raised two antioxidant enzymes, and entered senescence more often. Fluorescence work indicated both compounds slip between DNA bases with strong binding, while binding to a transport protein was moderate, favoring delivery. Computer modeling and docking supported the laboratory picture.
Catalog record
| CREATOR | Sevgi Kundu, Senem Akkoc, Yalçın Erzurumlu, Sadeq K Alhag, Lamya Ahmed Alkeridis, Mehran Feizi-Dehnayebi |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 53925 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |